LISTING ON NOTC
Nordic Nanovector (the “Company”) announces that its shares will be registered in the Norwegian OTC system (NOTC) from today, 7 July 2014, under the symbol ‘NANO’.
The share capital increase in connection with the recent NOK 250 million private placement at a subscription price of NOK 25 has been registered in the Norwegian Register of Business Enterprises and the number of shares currently outstanding is 22,821,375.
As resolved by the Company’s general meeting on 27 June 2014, the Company will effect a subsequent repair issue of up to 2,000,000 new shares at a subscription price of NOK 25 per share in August/September 2014. Further details will be announced in due course.
In addition, as described in the Company’s press release dated 27 September 2013, 1,666,666 shares will no later than 15 October 2014 be issued to HealthCap VI L.P. at a subscription price of NOK 15 in connection with the private placement completed in September 2013.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
